Nobuhiro Tanuma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nobuhiro Tanuma has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
Miyuki Nomura
Division of Cancer Chemotherapy Miyagi Cancer Center Research Institute Natori Japan
13 shared publicationsMami Morita
Division of Cancer Chemotherapy Miyagi Cancer Center Research Institute Natori Japan
9 shared publicationsYoji Yamashita
Division of Cancer Chemotherapy Miyagi Cancer Center Research Institute Natori Japan
8 shared publicationsTaku Sato
Division of Cancer Chemotherapy Miyagi Cancer Center Research Institute Natori Japan
7 shared publications- Tomoyoshi Soga
Institute for Advanced Biosciences Keio University Tsuruoka Yamagata Japan
7 shared publications Ikuro Sato
Department of Pathology, Miyagi Cancer Center Hospital, Natori, Japan
6 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models
Table S1. Metabolomics data from AML cell lines treated with FK866
- 28 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models
Table S1. Metabolomics data from AML cell lines treated with FK866
- Open Access
- 28 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models
Table S1. Metabolomics data from AML cell lines treated with FK866
- 28 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models
Table S1. Metabolomics data from AML cell lines treated with FK866
- Open Access
- 28 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models
Figure S5. Effects of NAMPTi and NFD on hematopoiesis, related to Fig. 4.
- 28 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models
Figure S5. Effects of NAMPTi and NFD on hematopoiesis, related to Fig. 4.
- Open Access
- 28 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models
Table S1. Metabolomics data from AML cell lines treated with FK866
- 28 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models
Table S1. Metabolomics data from AML cell lines treated with FK866
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 6 (10) , 2529-2540
Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models
Nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme in NAD biosynthesis, is a potential therapeutic target in cancer. Acute myeloid leukemia (AML) is among cancer types exhibiting high NAMPT dependence, and elevated NAMPT activity is implicated in venetoclax resistance. Thus, pharmacologic NAMPT inhibitors (NAMPTi) have been developed as a promising therapeutic approach in some cancers. However, our current knowledge of in vivo factors that determine NAMPTi therapeutic efficacy is incomplete. In this study, using mouse models we found that NAMPTi efficacy against AML is limited by dietary nicotinic acid (NA). Specifically, NA and NA riboside (NAR), an NA-derived metabolite, promoted NAD biosynthesis independent of NAMPT and rescued AML cells from NAMPTi-mediated toxicity in vitro. Importantly, in AML xenograft models, dietary NA restriction, which selectively reduces circulating NAR levels, enhanced antitumor efficacy of NAMPTis and prolonged animal survival. Although the combination treatment caused transient hematologic toxicity, peripheral blood cell counts largely recovered after treatment. Our findings highlight systemic NAD precursor metabolism, including NAR, as a determinant of responses to NAMPT-targeted therapies. We conclude that NA restriction may improve the therapeutic efficacy of NAMPTis in AML. Significance: NAMPT is a potential therapeutic target in AML, but factors governing treatment response remain undefined. Building on findings that dietary NA maintains circulating NAR levels, we demonstrate that this pathway provides a critical escape mechanism from NAMPT inhibition. We show that NA restriction sensitizes AML to NAMPTis, significantly improving survival in vivo, identifying systemic NAD precursor metabolism as a key determinant of therapeutic efficacy.
- 1 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 6 (10) , 2529-2540
Open AccessNicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models
Nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme in NAD biosynthesis, is a potential therapeutic target in cancer. Acute myeloid leukemia (AML) is among cancer types exhibiting high NAMPT dependence, and elevated NAMPT activity is implicated in venetoclax resistance. Thus, pharmacologic NAMPT inhibitors (NAMPTi) have been developed as a promising therapeutic approach in some cancers. However, our current knowledge of in vivo factors that determine NAMPTi therapeutic efficacy is incomplete. In this study, using mouse models we found that NAMPTi efficacy against AML is limited by dietary nicotinic acid (NA). Specifically, NA and NA riboside (NAR), an NA-derived metabolite, promoted NAD biosynthesis independent of NAMPT and rescued AML cells from NAMPTi-mediated toxicity in vitro. Importantly, in AML xenograft models, dietary NA restriction, which selectively reduces circulating NAR levels, enhanced antitumor efficacy of NAMPTis and prolonged animal survival. Although the combination treatment caused transient hematologic toxicity, peripheral blood cell counts largely recovered after treatment. Our findings highlight systemic NAD precursor metabolism, including NAR, as a determinant of responses to NAMPT-targeted therapies. We conclude that NA restriction may improve the therapeutic efficacy of NAMPTis in AML. Significance: NAMPT is a potential therapeutic target in AML, but factors governing treatment response remain undefined. Building on findings that dietary NA maintains circulating NAR levels, we demonstrate that this pathway provides a critical escape mechanism from NAMPT inhibition. We show that NA restriction sensitizes AML to NAMPTis, significantly improving survival in vivo, identifying systemic NAD precursor metabolism as a key determinant of therapeutic efficacy.
- Open Access
- 28 July 2026
- Published by Wiley in Cancer Science
- Vol. 117 (11) , 2997-3006
Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small‐Cell Lung Cancer Models
Small‐cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. We previously showed that nicotinic acid riboside (NAR) sustains NAD biosynthesis in vivo and compensates for NAMPT inhibition in SCLC models. Here, we evaluated combining NAMPT inhibition with dietary nicotinic acid (NA) restriction to suppress NAR‐dependent NAD biosynthesis. This combination showed enhanced antitumor activity consistent with synthetic lethality in SCLC CDX models and showed robust efficacy in PDX models, including those derived from chemotherapy‐refractory tumors. In most CDX models examined, combination therapy showed greater antitumor activity than standard chemotherapy with cisplatin and etoposide. Although we did observe transient leukopenia, the treatment was otherwise better tolerated than chemotherapy, with less impact on body weight and platelet counts. These findings support NAD metabolism–targeted therapy as a promising strategy to treat SCLC.
- 28 July 2026
- Published by Wiley in Cancer Science
- Vol. 117 (11) , 2997-3006
Open AccessNicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small‐Cell Lung Cancer Models
Small‐cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. We previously showed that nicotinic acid riboside (NAR) sustains NAD biosynthesis in vivo and compensates for NAMPT inhibition in SCLC models. Here, we evaluated combining NAMPT inhibition with dietary nicotinic acid (NA) restriction to suppress NAR‐dependent NAD biosynthesis. This combination showed enhanced antitumor activity consistent with synthetic lethality in SCLC CDX models and showed robust efficacy in PDX models, including those derived from chemotherapy‐refractory tumors. In most CDX models examined, combination therapy showed greater antitumor activity than standard chemotherapy with cisplatin and etoposide. Although we did observe transient leukopenia, the treatment was otherwise better tolerated than chemotherapy, with less impact on body weight and platelet counts. These findings support NAD metabolism–targeted therapy as a promising strategy to treat SCLC.
- Open Access
- 27 May 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (7) , 113200
The iron-sulfur cluster assembly factor FDX2 is required for tumor initiation but not for growth of established tumors in transplantation models
- 27 May 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (7) , 113200
Open AccessThe iron-sulfur cluster assembly factor FDX2 is required for tumor initiation but not for growth of established tumors in transplantation models
- Open Access
- 14 August 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (9) , 107678
FDX2, an iron-sulfur cluster assembly factor, is essential to prevent cellular senescence, apoptosis or ferroptosis of ovarian cancer cells
- 14 August 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (9) , 107678
Open AccessFDX2, an iron-sulfur cluster assembly factor, is essential to prevent cellular senescence, apoptosis or ferroptosis of ovarian cancer cells
- Open Access
- 6 February 2024
- Published by Wiley in FEBS Open Bio
- Vol. 14 (4) , 545-554
Oncogenic K‐RasG12V cannot overcome proliferation failure caused by loss of Ppp6c in mouse embryonic fibroblasts
Protein phosphatase 6 is a Ser/Thr protein phosphatase and its catalytic subunit is Ppp6c. Ppp6c is thought to be indispensable for proper growth of normal cells. On the other hand, loss of Ppp6c accelerates growth of oncogenic Ras‐expressing cells. Although it has been studied in multiple contexts, the role(s) of Ppp6c in cell proliferation remains controversial. It is unclear how oncogenic K‐Ras overcomes cell proliferation failure induced by Ppp6c deficiency; therefore, in this study, we attempted to shed light on how oncogenic K‐Ras modulates tumor cell growth. Contrary to our expectations, loss of Ppp6c decreased proliferation, anchorage‐independent growth in soft agar, and tumor formation of oncogenic Ras‐expressing mouse embryonic fibroblasts (MEFs). These findings show that oncogenic K‐RasG12V cannot overcome proliferation failure caused by loss of Ppp6c in MEFs.
- 6 February 2024
- Published by Wiley in FEBS Open Bio
- Vol. 14 (4) , 545-554
Open AccessOncogenic K‐RasG12V cannot overcome proliferation failure caused by loss of Ppp6c in mouse embryonic fibroblasts
Protein phosphatase 6 is a Ser/Thr protein phosphatase and its catalytic subunit is Ppp6c. Ppp6c is thought to be indispensable for proper growth of normal cells. On the other hand, loss of Ppp6c accelerates growth of oncogenic Ras‐expressing cells. Although it has been studied in multiple contexts, the role(s) of Ppp6c in cell proliferation remains controversial. It is unclear how oncogenic K‐Ras overcomes cell proliferation failure induced by Ppp6c deficiency; therefore, in this study, we attempted to shed light on how oncogenic K‐Ras modulates tumor cell growth. Contrary to our expectations, loss of Ppp6c decreased proliferation, anchorage‐independent growth in soft agar, and tumor formation of oncogenic Ras‐expressing mouse embryonic fibroblasts (MEFs). These findings show that oncogenic K‐RasG12V cannot overcome proliferation failure caused by loss of Ppp6c in MEFs.
- Open Access
- 13 December 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-15
Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma
Nicotinamide phosphoribosyltransferase (NAMPT) plays a major role in NAD biosynthesis in many cancers and is an attractive potential cancer target. However, factors dictating therapeutic efficacy of NAMPT inhibitors (NAMPTi) are unclear. We report that neuroendocrine phenotypes predict lung and prostate carcinoma vulnerability to NAMPTi, and that NAMPTi therapy against those cancers is enhanced by dietary modification. Neuroendocrine differentiation of tumor cells is associated with down-regulation of genes relevant to quinolinate phosphoribosyltransferase-dependent de novo NAD synthesis, promoting NAMPTi susceptibility in vitro. We also report that circulating nicotinic acid riboside (NAR), a non-canonical niacin absent in culture media, antagonizes NAMPTi efficacy as it fuels NAMPT-independent but nicotinamide riboside kinase 1-dependent NAD synthesis in tumors. In mouse transplantation models, depleting blood NAR by nutritional or genetic manipulations is synthetic lethal to tumors when combined with NAMPTi. Our findings provide a rationale for simultaneous targeting of NAR metabolism and NAMPT therapeutically in neuroendocrine carcinoma.
- 13 December 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-15
Open AccessNiacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma
Nicotinamide phosphoribosyltransferase (NAMPT) plays a major role in NAD biosynthesis in many cancers and is an attractive potential cancer target. However, factors dictating therapeutic efficacy of NAMPT inhibitors (NAMPTi) are unclear. We report that neuroendocrine phenotypes predict lung and prostate carcinoma vulnerability to NAMPTi, and that NAMPTi therapy against those cancers is enhanced by dietary modification. Neuroendocrine differentiation of tumor cells is associated with down-regulation of genes relevant to quinolinate phosphoribosyltransferase-dependent de novo NAD synthesis, promoting NAMPTi susceptibility in vitro. We also report that circulating nicotinic acid riboside (NAR), a non-canonical niacin absent in culture media, antagonizes NAMPTi efficacy as it fuels NAMPT-independent but nicotinamide riboside kinase 1-dependent NAD synthesis in tumors. In mouse transplantation models, depleting blood NAR by nutritional or genetic manipulations is synthetic lethal to tumors when combined with NAMPTi. Our findings provide a rationale for simultaneous targeting of NAR metabolism and NAMPT therapeutically in neuroendocrine carcinoma.